Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 11/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356310 | 0.81 | ALDH1A1 (0.44) | CYP11B1KDM4EKCNJ1ALDH1A1 | |
| SCHEMBL14762040 | 0.79 | AOC3 (0.37) | CYP11B1KMT2AMEN1KDM4EKCNJ1 | |
| SCHEMBL31607175 | 0.79 | ALDH1A1 (0.43) | CYP11B1KDM4EKCNJ1ALDH1A1 | |
| SCHEMBL31607172 | 0.79 | ALDH1A1 (0.43) | CYP11B1KDM4EKCNJ1ALDH1A1 | |
| SCHEMBL31607177 | 0.79 | ALDH1A1 (0.43) | CYP11B1KDM4EKCNJ1ALDH1A1 | |
| SCHEMBL948672 | 0.77 | KEAP1 (0.58) | CYP11B1KMT2AMEN1CYP19A1KDM4E | |
| SCHEMBL20636645 | 0.74 | ALDH1A1 (0.44) | CYP11B1KDM4EKCNJ1ALDH1A1 | |
| SCHEMBL42126 | 0.74 | CCR1 (0.64) | JMJD6KMT2ACYP19A1KEAP1KDM5B | |
| SCHEMBL24409244 | 0.73 | TRIM24 (0.42) | CYP11B1KMT2AMEN1KDM4EKCNJ1 | |
| SCHEMBL19925989 | 0.73 | CYP11B1 (0.49) | CYP11B1KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378256-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-05 | — | — | US | disclosed |
| US-12024505-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20230303541-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-28 | — | — | US | disclosed |
| EP-3643718-B1 | HETEROCYCLIC COMPOUND AND ITS USE AS POSITIVE ALLOSTERIC MODULATOR OF THE CHOLINERGIC MUSCARINIC M1 RECEPTOR. | TAKEDA PHARMACEUTICALS CO (JP) | 2023-07-26 | — | — | EP | disclosed |
| CN-110709401-B | Heterocyclic compounds | 武田药品工业株式会社 | 2023-06-13 | — | — | CN | disclosed |
| US-11560372-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-24 | — | — | US | disclosed |
| EP-3612527-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICALS CO (JP) | 2022-07-20 | — | — | EP | disclosed |
| US-11236099-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| US-20220017530-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| US-20210292308-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-23 | — | — | US | disclosed |
| US-20210139491-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| EP-3643718-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017530-A1 | HETEROCYCLIC COMPOUND | SLC10A2, ALPI, VIP | JMJD6 2153/4885CYP11B1 302/4885KMT2A 528/4885 |
| US-12378256-B2 | Heterocyclic compound | SLC10A2, ALPI, VIP | JMJD6 2153/4885CYP11B1 302/4885KMT2A 528/4885 |
| US-12024505-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | CHRM3, CHRNA1, CHRM5 | JMJD6 1683/4885CYP11B1 884/4885KMT2A 936/4885 |
| US-20230303541-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | CHRM3, CHRNA1, CHRM5 | JMJD6 1683/4885CYP11B1 884/4885KMT2A 936/4885 |
| US-20210139491-A1 | HETEROCYCLIC COMPOUND | SLC10A2, ALPI, VIP | JMJD6 2153/4885CYP11B1 302/4885KMT2A 528/4885 |
| US-20210292308-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | CHRM3, CHRNA1, CHRM5 | JMJD6 1691/4885CYP11B1 878/4885KMT2A 908/4885 |
| US-11560372-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | CHRM3, CHRNA1, CHRM5 | JMJD6 1691/4885CYP11B1 878/4885KMT2A 908/4885 |
| US-11236099-B2 | Heterocyclic compound | SLC10A2, ALPI, VIP | JMJD6 2153/4885CYP11B1 302/4885KMT2A 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.